A Multicentre, Open Label, Nonrandomised, Non-Interventional, Observational, Safety Study in Subjects Using Insulin Aspart (NovoRapid) or Soluble Human Insulin for the Treatment of Diabetes Mellitus the UPGRADE Study.
Latest Information Update: 03 Nov 2016
Price :
$35 *
At a glance
- Drugs Insulin aspart (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms UPGRADE
- Sponsors Novo Nordisk
- 05 Jun 2009 Actual patient number (4143) added as reported by ClinicalTrials.gov.
- 05 Jun 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov
- 05 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.